LL-37 (human cathelicidin)

hCAP18 (134–170); CAP-18 derived antimicrobial peptide

Identity

Sequence

LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES

Three-letter

Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser

Length

37 residues

Modifications

None (free acid)

Formula

C205H340N60O53

Average mass

4493.3 Da

CAS

154947-66-7

Specifications (per released lot)

Purity

≥ 98 % by RP-HPLC, 220 nm

Identity

ESI-MS; observed mass within 0.1 % of calculated

Form

White to off-white lyophilized powder

Counter-ion

Trifluoroacetate; acetate on request

Net peptide content

Reported per lot (typically 70–90 % of gross mass; the balance is counter-ion and water)

Vial sizes

5 mg · 10 mg · 25 mg net peptide; bulk on quotation

Storage

−20 °C, desiccated, protected from light. Ships at ambient temperature.

Documents

Lot certificate of analysis (COA library); safety data sheet in WHMIS 2015 format, enclosed with every shipment

Research context

The only human cathelicidin antimicrobial peptide, released from hCAP18. Used in antimicrobial, LPS-neutralization, biofilm and innate-immunity research.

Literature context is provided to help laboratories identify the reagent. It is not a claim about effects in people and does not describe any use outside in-vitro or approved animal research.